DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)

Market Cap	138.19B +1.6%
Revenue (ttm)	238.39B -6.0%
Net Income	770.31M -95.0%
EPS	28.46 -94.9%
Shares Out	27.04M
PE Ratio	179.53
Forward PE	n/a
Dividend	120.00 (2.52%)
Ex-Dividend Date	Dec 29, 2025

Volume	137,995
Average Volume	249,589
Open	5,200.00
Previous Close	5,210.00
Day's Range	5,170.00 - 5,470.00
52-Week Range	4,720.00 - 6,390.00
Beta	0.47
RSI	43.99
Earnings Date	Mar 19, 2026

About DongKoo Bio & Pharma

DongKoo Bio & Pharma Co., Ltd. manufactures and sells pharmaceuticals in South Korea. The company provides prescription drugs, such as antihistamines, dermatological oral medications, ophthalmic solutions, skeletal muscle relaxants, anti-inflammatory enzymes, antivirals, antibacterial agents, and for the treatment of allergies, liver diseases, mental illnesses, obesity, brain nervous, and endocrine systems; over-the-counter medicines, such as dermatological external preparations, antifungal agents, active probiotic intestinal supplements, antip...

• Industry: Pharmaceutical Preparations
• Founded: 1970
• Employees: 404
• Stock Exchange: KOSDAQ
• Ticker Symbol: 006620

Financial Performance

In 2024, DongKoo Bio & Pharma's revenue was 249.27 billion, an increase of 15.57% compared to the previous year's 215.69 billion. Earnings were 2.04 billion, a decrease of -82.77%.